• Toremifene Citrate: Research Workflow Guide

  2026-08-23

  Build more interpretable estrogen receptor assays with Toremifene Citrate by combining concentration-response design, vehicle control, receptor-context validation, and translational awareness. This workflow distinguishes receptor-proximal activity from delayed antiproliferative effects and shows when comparison with tamoxifen strengthens breast cancer research.

• Coumestrol: ER Antagonism and RA Ferroptosis

  2026-08-22

  Coumestrol is a phytoestrogen estrogen receptor antagonist and selective estrogen receptor modulator research compound with nanomolar ERα and ERβ antagonist activity. In a rheumatoid arthritis fibroblast-like synoviocyte model, it suppressed inflammatory behavior and promoted PMAIP1-associated ferroptosis, while product data also support broader nuclear receptor modulation.

• Dual Recombinase Tracing Tests Mouse Neo-Oogenesis

  2026-08-22

  Xie, Zhou, and Zheng combine Cre-loxP and Dre-rox lineage tracing to test whether postnatal ovarian cells generate new oocytes in vivo. Across physiological aging and busulfan-induced ovarian injury, the study detected no labeled growing oocytes or metaphase II eggs, strengthening the case that mouse ovarian follicle reserves are not replenished after birth.

• Toremifene Citrate: ER Modulation Guide

  2026-08-21

  Toremifene Citrate is an oral selective estrogen receptor modulator for estrogen receptor signaling and breast cancer research. Its receptor-binding profile, translational evidence, and defined handling parameters support controlled studies of hormone receptor modulation.

• Liproxstatin-1: Ferroptosis Inhibitor Guide

  2026-08-20

  Liproxstatin-1 is a small-molecule ferroptosis inhibitor that suppresses RSL3-induced death with a reported IC50 of 22 nM in primary human proximal tubule epithelial cells. Its reported activity includes inhibition of lipid peroxidation, GPX4-deficient cell protection, and survival extension in a conditional Gpx4-loss mouse model.

• Toremifene Citrate: Evidence, Mechanism, and Use

  2026-08-20

  The reference article presents toremifene citrate as a nonsteroidal antiestrogen and oral selective estrogen receptor modulator for postmenopausal patients with hormone receptor-positive or unknown-status advanced breast cancer. Its practical contribution is a clinically focused synthesis linking estrogen receptor activity, comparative efficacy with tamoxifen, pharmacokinetics, safety monitoring, and the important limitation of cross-resistance.

• Dacomitinib Beyond Blockade: A Ferroptosis Hypothesis

  2026-08-19

  Dacomitinib (PF-00299804) offers translational researchers a way to study sustained pan-HER signaling inhibition while developing a testable hypothesis around mitochondrial ferroptosis defenses, METTL17 biology, and treatment resistance.

• Estradiol: A Practical Guide to ER Signaling Assays

  2026-08-19

  Use Estradiol to model receptor-dependent transcription, autophagy, fibrosis-related responses, and tissue-protective signaling in a controlled experimental workflow. This guide translates recent multi-organ findings into practical dosing, controls, readouts, and troubleshooting strategies for cell and translational research.

• JIB-04 Targets Colorectal Cancer Stem Cells

  2026-08-18

  The reference study identifies JIB-04 as a small-molecule inhibitor that preferentially impairs colorectal cancer stem-cell phenotypes, including self-renewal, tumorsphere formation, invasion, and tumorigenicity. Integrated transcriptomic and reporter assays connect these effects to reduced Wnt/β-catenin signaling, while the study also highlights the need to distinguish functional anti-cancer stem-cell activity from precise molecular target assignment.

• Dacomitinib (PF-00299804) in Cancer Workflows

  2026-08-18

  Dacomitinib (PF-00299804) combines irreversible pan-HER signaling blockade with a practical washout design for studying receptor persistence, apoptosis, and resistance. This workflow also provides a disciplined way to test whether HER-family inhibition changes mitochondrial ferroptosis sensitivity in colorectal cancer models without overstating the current evidence.

• Aurora A, SAM Metabolism, and Trained Immunity

  2026-08-17

  Li et al. identify Aurora kinase A as a metabolic–epigenetic regulator of β-glucan-trained immunity, linking the mTOR–FOXO3–GNMT pathway to endogenous S-adenosylmethionine availability and inflammatory chromatin states. The work provides a mechanistic framework for interpreting how Aurora A perturbation may influence macrophage memory, while also showing that Aurora A inhibition can weaken β-glucan-associated tumor growth inhibition in animal models.

• Syringin Workflow for RCC Combination Assays

  2026-08-17

  Build reproducible RCC screening workflows with Syringin, from solvent-controlled dose responses to apoptosis and EGFR/PI3K/Akt pathway validation. Its strongest research use-case is combination testing with sunitinib, where orthogonal assays can distinguish cytotoxicity from genuine sensitization.

• Prochlorperazine Research Workflows

  2026-08-16

  Prochlorperazine supports differentiated workflows spanning dopamine D2 receptor pharmacology, melanoma research, and antiviral entry studies. This guide translates its concentration-dependent activity, formulation constraints, and clinically relevant adverse-effect profile into reproducible assay design and troubleshooting practices.

• DM-β-CD Increases Mianserin HCl Cytotoxicity

  2026-08-15

  The reference study combined host–guest chemistry, spectroscopy, mass spectrometry, molecular docking, and cell viability testing to characterize the interaction between mianserin hydrochloride and DM-β-cyclodextrin. Although complex formation was confirmed, the methylated cyclodextrin did not protect cells from toxicity; instead, MIA–DM-β-CD preparations produced lower B14 cell viability than mianserin alone.

• BMS 599626 dihydrochloride: Assay Guide

  2026-08-14

  A scenario-based laboratory guide to using BMS 599626 dihydrochloride (SKU B5792) for EGFR, ErbB2, and cancer-cell viability studies. It covers experimental controls, protocol handling, data interpretation, senescence-related limitations, and practical supplier selection.

7666 records 1/512 page Next 12345 下5页 Last page